FENC logo

Fennec Pharmaceuticals (FENC) Free Cash Flow

Annual FCF

-$17.14 M
+$915.00 K+5.07%

December 31, 2023


Summary


Performance

FENC Free Cash Flow Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherFENCcash flowmetrics:

Quarterly FCF

-$2.21 M
+$6.18 M+73.70%

September 30, 2024


Summary


Performance

FENC Quarterly FCF Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherFENCcash flowmetrics:

TTM FCF

$23.59 M
+$554.00 K+2.40%

September 30, 2024


Summary


Performance

FENC TTM FCF Chart

Add series to chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Highlights

High & Low

Earnings dates

OtherFENCcash flowmetrics:

Free Cash Flow Formula

FCF = Cash From Operations − CAPEX

FENC Free Cash Flow Trends

PeriodPeriodAnnualAnnualQuarterlyQuarterlyTTMTTM
1 y1 year+5.1%+73.7%+2.4%
3 y3 years-9.9%+60.4%+213.6%
5 y5 years-119.0%+60.4%+213.6%

FENC Free Cash Flow Highs & Lows

PeriodPeriodAnnual vs highAnnual vs highAnnual vs lowAnnual vs lowQuarter. vs highQuarter. vs highQuarter. vs lowQuarter. vs lowTTM vs highTTM vs highTTM vs lowTTM vs low
3 y3-year-20.5%+5.1%-105.7%+73.7%-14.1%+210.6%
5 y5-year-89.2%+5.1%-105.7%+73.7%-14.1%+210.6%
alltimeall time-1264.7%+5.1%-105.7%+73.7%-14.1%+210.6%

Fennec Pharmaceuticals Free Cash Flow History

DateAnnualQuarterlyTTM
Sep 2024
-
-$2.21 M(-73.7%)
$23.59 M(+2.4%)
Jun 2024
-
-$8.39 M(-121.5%)
$23.04 M(-16.2%)
Mar 2024
-
$39.05 M(-903.4%)
$27.48 M(-260.3%)
Dec 2023
-$17.14 M(-5.1%)
-$4.86 M(+76.1%)
-$17.14 M(-10.2%)
Sep 2023
-
-$2.76 M(-30.1%)
-$19.09 M(-10.5%)
Jun 2023
-
-$3.95 M(-29.2%)
-$21.34 M(+2.7%)
Mar 2023
-
-$5.58 M(-18.0%)
-$20.78 M(+15.1%)
Dec 2022
-$18.06 M(+27.0%)
-$6.80 M(+35.8%)
-$18.06 M(+24.5%)
Sep 2022
-
-$5.01 M(+47.8%)
-$14.50 M(+16.5%)
Jun 2022
-
-$3.39 M(+18.7%)
-$12.45 M(-7.7%)
Mar 2022
-
-$2.86 M(-12.0%)
-$13.48 M(-5.2%)
Dec 2021
-$14.22 M(-8.8%)
-$3.25 M(+9.7%)
-$14.22 M(-0.3%)
Sep 2021
-
-$2.96 M(-33.2%)
-$14.26 M(-14.9%)
Jun 2021
-
-$4.43 M(+23.2%)
-$16.75 M(+8.5%)
Mar 2021
-
-$3.59 M(+9.4%)
-$15.44 M(-1.0%)
Dec 2020
-$15.60 M(+72.1%)
-$3.28 M(-39.7%)
-$15.60 M(+12.2%)
Sep 2020
-
-$5.45 M(+74.8%)
-$13.90 M(+30.0%)
Jun 2020
-
-$3.12 M(-16.9%)
-$10.69 M(+3.5%)
Mar 2020
-
-$3.75 M(+135.8%)
-$10.33 M(+14.0%)
Dec 2019
-$9.06 M(+15.8%)
-$1.59 M(-28.9%)
-$9.06 M(-12.9%)
Sep 2019
-
-$2.23 M(-18.9%)
-$10.40 M(+6.5%)
Jun 2019
-
-$2.76 M(+11.2%)
-$9.76 M(+13.8%)
Mar 2019
-
-$2.48 M(-15.4%)
-$8.58 M(+9.6%)
Dec 2018
-$7.83 M(+114.9%)
-$2.93 M(+83.2%)
-$7.83 M(+25.9%)
Sep 2018
-
-$1.60 M(+1.8%)
-$6.22 M(+11.5%)
Jun 2018
-
-$1.57 M(-9.1%)
-$5.58 M(+18.8%)
Mar 2018
-
-$1.73 M(+30.8%)
-$4.69 M(+28.9%)
Dec 2017
-$3.64 M(+71.4%)
-$1.32 M(+37.8%)
-$3.64 M(+24.2%)
Sep 2017
-
-$958.00 K(+39.2%)
-$2.93 M(+16.4%)
Jun 2017
-
-$688.00 K(+1.9%)
-$2.52 M(+9.5%)
Mar 2017
-
-$675.00 K(+10.5%)
-$2.30 M(+8.3%)
Dec 2016
-$2.12 M(+14.1%)
-$611.00 K(+12.3%)
-$2.12 M(+9.7%)
Sep 2016
-
-$544.00 K(+15.7%)
-$1.94 M(+1.8%)
Jun 2016
-
-$470.00 K(-5.8%)
-$1.90 M(-2.1%)
Mar 2016
-
-$499.00 K(+17.7%)
-$1.94 M(+4.4%)
Dec 2015
-$1.86 M(+9.6%)
-$424.00 K(-16.7%)
-$1.86 M(-2.3%)
Sep 2015
-
-$509.00 K(-0.4%)
-$1.91 M(+3.6%)
Jun 2015
-
-$511.00 K(+22.2%)
-$1.84 M(+5.8%)
Mar 2015
-
-$418.00 K(-10.7%)
-$1.74 M(+2.4%)
Dec 2014
-$1.70 M(-23.1%)
-$468.00 K(+5.6%)
-$1.70 M(+1.4%)
Sep 2014
-
-$443.00 K(+8.0%)
-$1.68 M(-1.5%)
Jun 2014
-
-$410.00 K(+8.5%)
-$1.70 M(-22.0%)
Mar 2014
-
-$378.00 K(-15.1%)
-$2.18 M(-1.3%)
Dec 2013
-$2.21 M(-26.2%)
-$445.00 K(-5.1%)
-$2.21 M(-4.8%)
Sep 2013
-
-$469.00 K(-47.2%)
-$2.32 M(-10.0%)
Jun 2013
-
-$889.00 K(+118.4%)
-$2.58 M(-8.6%)
Mar 2013
-
-$407.00 K(-26.9%)
-$2.82 M(-5.7%)
DateAnnualQuarterlyTTM
Dec 2012
-$2.99 M(-7.2%)
-$557.00 K(-23.3%)
-$2.99 M(-6.6%)
Sep 2012
-
-$726.00 K(-35.9%)
-$3.20 M(+2.9%)
Jun 2012
-
-$1.13 M(+96.0%)
-$3.11 M(+13.0%)
Mar 2012
-
-$578.00 K(-24.6%)
-$2.76 M(-14.6%)
Dec 2011
-$3.23 M(+67.3%)
-$767.00 K(+20.6%)
-$3.23 M(+3.6%)
Sep 2011
-
-$636.00 K(-17.9%)
-$3.11 M(+2.8%)
Jun 2011
-
-$775.00 K(-26.0%)
-$3.03 M(+14.7%)
Mar 2011
-
-$1.05 M(+60.0%)
-$2.64 M(+36.9%)
Dec 2010
-$1.93 M(-58.9%)
-$655.00 K(+19.1%)
-$1.93 M(+32.4%)
Sep 2010
-
-$550.00 K(+42.5%)
-$1.46 M(-7.7%)
Jun 2010
-
-$386.00 K(+14.5%)
-$1.58 M(-42.0%)
Mar 2010
-
-$337.00 K(+84.2%)
-$2.72 M(-41.9%)
Dec 2009
-$4.69 M(-56.7%)
-$183.00 K(-72.8%)
-$4.69 M(-34.2%)
Sep 2009
-
-$672.00 K(-56.1%)
-$7.13 M(-19.7%)
Jun 2009
-
-$1.53 M(-33.5%)
-$8.87 M(-13.5%)
Mar 2009
-
-$2.30 M(-12.2%)
-$10.26 M(-5.2%)
Dec 2008
-$10.82 M(-19.1%)
-$2.62 M(+8.4%)
-$10.82 M(+4.3%)
Sep 2008
-
-$2.42 M(-17.2%)
-$10.38 M(+1.8%)
Jun 2008
-
-$2.92 M(+2.0%)
-$10.19 M(+3.9%)
Mar 2008
-
-$2.86 M(+31.7%)
-$9.81 M(-26.7%)
Dec 2007
-$13.38 M(-0.8%)
-$2.17 M(-2.6%)
-$13.38 M(-7.7%)
Sep 2007
-
-$2.23 M(-11.9%)
-$14.49 M(-6.9%)
Jun 2007
-
-$2.54 M(-60.6%)
-$15.55 M(-6.8%)
Mar 2007
-
-$6.43 M(+95.9%)
-$16.70 M(+23.9%)
Dec 2006
-$13.48 M(+9.0%)
-$3.29 M(-0.5%)
-$13.48 M(-1.7%)
Sep 2006
-
-$3.30 M(-10.3%)
-$13.72 M(-5.3%)
Jun 2006
-
-$3.68 M(+14.3%)
-$14.49 M(+11.7%)
Mar 2006
-
-$3.22 M(-8.7%)
-$12.98 M(+5.0%)
Dec 2005
-$12.36 M(+101.2%)
-$3.52 M(-13.5%)
-$12.36 M(+39.9%)
Sep 2005
-
-$4.07 M(+88.6%)
-$8.84 M(+23.7%)
Jun 2005
-
-$2.16 M(-17.1%)
-$7.15 M(+8.1%)
Mar 2005
-
-$2.61 M(+9.4%)
-$6.61 M(-7.9%)
Sep 2004
-
-$2.38 M(+46.8%)
-$7.18 M(+16.8%)
Jun 2004
-$6.14 M(+3.8%)
-$1.62 M(-11.4%)
-$6.14 M(+5.5%)
Mar 2004
-
-$1.83 M(+36.4%)
-$5.82 M(-10.4%)
Dec 2003
-
-$1.34 M(-0.5%)
-$6.50 M(+1.4%)
Sep 2003
-
-$1.35 M(+3.7%)
-$6.41 M(+8.2%)
Jun 2003
-$5.92 M(+67.8%)
-$1.30 M(-48.0%)
-$5.92 M(+1.0%)
Mar 2003
-
-$2.50 M(+99.7%)
-$5.86 M(+44.8%)
Dec 2002
-
-$1.25 M(+45.5%)
-$4.05 M(+14.9%)
Sep 2002
-
-$861.30 K(-30.7%)
-$3.52 M(-0.1%)
Jun 2002
-$3.53 M(+16.8%)
-$1.24 M(+80.1%)
-$3.53 M(+54.4%)
Mar 2002
-
-$689.80 K(-5.4%)
-$2.29 M(+43.2%)
Dec 2001
-
-$729.40 K(-15.8%)
-$1.60 M(+84.2%)
Sep 2001
-
-$866.40 K
-$866.40 K
Jun 2001
-$3.02 M(+140.4%)
-
-
Jun 2000
-$1.26 M
-
-

FAQ

  • What is Fennec Pharmaceuticals annual free cash flow?
  • What is the all time high annual FCF for Fennec Pharmaceuticals?
  • What is Fennec Pharmaceuticals annual FCF year-on-year change?
  • What is Fennec Pharmaceuticals quarterly free cash flow?
  • What is the all time high quarterly FCF for Fennec Pharmaceuticals?
  • What is Fennec Pharmaceuticals quarterly FCF year-on-year change?
  • What is Fennec Pharmaceuticals TTM free cash flow?
  • What is the all time high TTM FCF for Fennec Pharmaceuticals?
  • What is Fennec Pharmaceuticals TTM FCF year-on-year change?

What is Fennec Pharmaceuticals annual free cash flow?

The current annual FCF of FENC is -$17.14 M

What is the all time high annual FCF for Fennec Pharmaceuticals?

Fennec Pharmaceuticals all-time high annual free cash flow is -$1.26 M

What is Fennec Pharmaceuticals annual FCF year-on-year change?

Over the past year, FENC annual free cash flow has changed by +$915.00 K (+5.07%)

What is Fennec Pharmaceuticals quarterly free cash flow?

The current quarterly FCF of FENC is -$2.21 M

What is the all time high quarterly FCF for Fennec Pharmaceuticals?

Fennec Pharmaceuticals all-time high quarterly free cash flow is $39.05 M

What is Fennec Pharmaceuticals quarterly FCF year-on-year change?

Over the past year, FENC quarterly free cash flow has changed by +$6.18 M (+73.70%)

What is Fennec Pharmaceuticals TTM free cash flow?

The current TTM FCF of FENC is $23.59 M

What is the all time high TTM FCF for Fennec Pharmaceuticals?

Fennec Pharmaceuticals all-time high TTM free cash flow is $27.48 M

What is Fennec Pharmaceuticals TTM FCF year-on-year change?

Over the past year, FENC TTM free cash flow has changed by +$554.00 K (+2.40%)